Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,700 result(s) found for: placebo. Displaying page 238 of 635.
    «« First « Previous 234  235  236  237  238  239  240  241  242  Next» Last»»
    EudraCT Number: 2006-000091-32 Sponsor Protocol Number: 20050225 Start Date*: 2006-10-25
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women wit...
    Medical condition: HER2 Negative Locally Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-016604-23 Sponsor Protocol Number: CACZ885I2207 Start Date*: 2010-05-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...
    Medical condition: Impaired Glucose Tolerance and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023775-25 Sponsor Protocol Number: 3652-CL-0019 Start Date*: 2011-08-02
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacoki...
    Medical condition: Chronic abacterial Prostatitis/Chronic Pelvic Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10064189 Chronic pelvic pain syndrome LLT
    14.1 100000004872 10009109 Chronic prostatitis LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) CZ (Completed) LT (Completed) LV (Completed) PL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000261-21 Sponsor Protocol Number: 1399-0003 Start Date*: 2019-10-08
    Sponsor Name:Boehringer Ingelheim
    Full Title: A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy t...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000305-21 Sponsor Protocol Number: S306.2.008 Start Date*: 2006-09-06
    Sponsor Name:Solvay Pharmaceuticals
    Full Title: A randomized, placebo-controlled, double-blind, six-arm, dose escalation, multi-center study to evaluate the efficacy and safety of SLV306: 150, 300, 600 mg once daily, 150-300 mg twice daily and a...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) DK (Completed) HU (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2007-003684-41 Sponsor Protocol Number: 6213-006-03 Start Date*: 2007-11-01
    Sponsor Name:MSD Finland Oy
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Assess the Efficacy and Tolerability of MK-6213 Co-Administered With Atorvastatin in Patients with Primary Hypercho...
    Medical condition: Primary hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002817-78 Sponsor Protocol Number: D5670C00007-Amendment1 Start Date*: 2017-12-06
    Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca
    Full Title: An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Subjects with Type 2 Diabetes Mellitus ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004932-20 Sponsor Protocol Number: 1311.14 Start Date*: 2015-06-05
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 w...
    Medical condition: Severe Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) NL (Completed) DE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002248-40 Sponsor Protocol Number: F1J-MC-HMGC Start Date*: 2008-08-04
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pain
    Medical condition: Chronic low back pain (CLBP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024891 Low back pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005797-44 Sponsor Protocol Number: CL2-05985-005 Start Date*: 2007-03-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination compared with each component (perindopril arginine 3.5 mg and amlodipine 2.5 mg) and with pe...
    Medical condition: Essential arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FR (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-019760-36 Sponsor Protocol Number: T05018-2004 Start Date*: 2010-11-22
    Sponsor Name:Grifols Therapeutics, Incorporated
    Full Title: A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Comp...
    Medical condition: acute peripheral arterial occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10057525 Peripheral artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-002187-22 Sponsor Protocol Number: 001 Start Date*: 2005-04-05
    Sponsor Name:Ullevål University Hospital
    Full Title: Scandinavian Candesartan Acute Stroke Trial
    Medical condition: Acute stroke (ischemic or haemoragic)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Completed) BE (Completed) EE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004989-17 Sponsor Protocol Number: KRM-306 Start Date*: 2007-10-17
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation [...]
    1. Mitsubishi Tanabe Pharma Corporation
    2. KUREHA CORPORATION
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003320-23 Sponsor Protocol Number: AC-055H301 Start Date*: 2017-10-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent subjects.
    Medical condition: Congenital Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045545 Univentricular heart PT
    21.1 10042613 - Surgical and medical procedures 10065950 Cavopulmonary anastomosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) FR (Completed) PL (Completed) IE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-003302-27 Sponsor Protocol Number: ANAVEX2-73-AD-004 Start Date*: 2020-01-22
    Sponsor Name:Anavex Germany GmbH
    Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000956-37 Sponsor Protocol Number: TILD-19-19 Start Date*: 2021-06-18
    Sponsor Name:Sun Pharmaceutical industries Ltd
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002125-19 Sponsor Protocol Number: 9494 Start Date*: 2016-06-20
    Sponsor Name:CHU MontpellierCentre administratif André Benech,
    Full Title: A phase IIb, prospective, multicentre, double-blind, triple-arm, randomized versus placebo trial, to assess the efficacy of a single injection of either 2 or 10 x 106 autologous adipose derived mes...
    Medical condition: Active knee Osteoarthritis (mild to moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000068-40 Sponsor Protocol Number: FAIR-HF2 Start Date*: 2017-01-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. Ferric carboxymaltose Assessment of morbidity and mortality in patients with IRon de...
    Medical condition: Systolic heart failure associated with iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10074631 Systolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PT (Completed) SI (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 234  235  236  237  238  239  240  241  242  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 15:38:35 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA